OverviewSuggest Edit
Regenx Biosciences, LLC, a biopharmaceutical company, develops therapeutics and research tools based on adeno-associated viral (AAV) vectors. The Company offers NAV, a gene delivery technology that includes recombinant adeno-associated viral vectors. Its technology is used for the treatment of metabolic disorders, muscle diseases, hematologic disorders, ocular diseases, and neurodegenerative disorders; and clinical trails in therapeutic areas, such as inherited diseases, CNS disorders, heart failure, and vaccines. The Company also offers reagent services for various applications, including molecular therapies, understanding biological activity and target validation, creating disease models and screening in vivo, and genome-wide association studies. In addition, Regenxoffers custom products and services, including AAV plasmids, AAV Vector reporter systems, and custom AAV vectors to the researchers.
| Type | Public | |
| Founded | 2009 | |
| HQ | Rockville, US | Map |
| Website | regenxbio.com | |
| Employee Ratings | More |
Recent NewsAll News
- Optogenetic Market 2018 Enthralling Growth at A CAGR Of 17% | By Product Type Light Instruments, Actuators, Sensors – Declares MRFR
- 3 Things In Biotech, May 5: Mallinckrodt Snubbed, Regenxbio Races, Portola Surprises
- OncoSec: The Underlying Science Of ImmunoPulse Powers A Potential Winner
- Rounds Report: Regenxbio Surged Higher While Celldex Tumbled Due To A Negative Clinical Binary
Key People/Management at Regenxbio
Ken Mills
President and Chief Executive Officer
Vit Vasista
CFO
Stephen Yoo
Chief Medical Officer
Olivier Danos
Chief Scientific Officer
Curran Simpson
Senior Vice President, Technical Operations
Kimberly Sloan
Senior Vice President, Human Resources
Regenxbio Office Locations
Regenxbio has an office in Rockville
Rockville, US (HQ)
9712 Medical Center Dr #100
Regenxbio Financials and Metrics
Regenxbio Revenue
Regenxbio's revenue was reported to be $218.51 m in FY, 2018
| USD | |
|---|---|
Revenue (Q1, 2019) | 884.0k |
Gross profit (Q1, 2019) | 855.0k |
Gross profit margin (Q1, 2019), % | 96.7% |
Net income (Q1, 2019) | (32.2m) |
EBIT (Q1, 2019) | (35.9m) |
Market capitalization (21-May-2019) | 1.6b |
Closing stock price (21-May-2019) | 43.0 |
Cash (31-Mar-2019) | 55.9m |
Regenxbio's current market capitalization is $1.6 b.
Annual
Annual
Quarterly
| USD | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 205.3m | 35.5m | 30.1m | 28.1m | 82.0m | 57.6m | 59.9m | 71.9m | 106.9m | 142.4m | 55.9m |
Accounts Receivable | 2.0m | 783.0k | 679.0k | 228.0k | 50.0k | 884.0k | 26.0m | 739.0k | 2.6m | 8.4m | |
Current Assets | 215.5m | 105.6m | 97.9m | 96.6m | 148.8m | 165.8m | 172.2m | 262.7m | 293.3m | 386.4m | 303.9m |
PP&E | 385.0k | 1.3m | 2.9m | 5.8m | 11.1m | 11.5m | 11.5m | 14.8m | 16.7m | 19.9m | 23.1m |
Annual
Quarterly
| USD | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (17.6m) | (10.8m) | (25.2m) | (43.4m) | (22.0m) | (36.5m) | (57.2m) | 104.2m | 114.8m | 95.6m | (32.2m) |
Depreciation and Amortization | 43.0k | 48.0k | 104.0k | 264.0k | 554.0k | 1.3m | 2.0m | 834.0k | 1.7m | 2.7m | 1.6m |
Accounts Payable | 317.0k | (182.0k) | 930.0k | 3.6m | 2.5m | 2.7m | 1.1m | 477.0k | (340.0k) | 156.0k | 316.0k |
Cash From Operating Activities | (18.1m) | (7.9m) | (16.3m) | (28.1m) | (17.5m) | (27.0m) | (44.2m) | 58.1m | 128.3m | 108.8m | (29.3m) |
| USD | Y, 2019 |
|---|---|
Revenue/Employee | 4.6k |
Financial Leverage | 1.1 x |
Regenxbio Online and Social Media Presence
695 Twitter followers
Regenxbio has 695 Twitter Followers. The number of followers has increased 6% month over month and increased 17.8% quarter over quarter
Twitter Engagement Stats for @regenxbio
89
Tweets
127
Following
695
Followers
6
Tweets last 30 days
4.2
Avg. likes per Tweet
100%
Tweets with engagement
Regenxbio News and Updates
June 05, 2018
Optogenetic Market 2018 Enthralling Growth at A CAGR Of 17% | By Product Type Light Instruments, Actuators, Sensors – Declares MRFR
This report provides in-depth qualitative and overall analysis of the” Optogenetic Market” on a global and regional level from 2018 to 2023. The study also provides a comprehensive review of restraints, Market Dynamics, drivers and opportunities along with their impact on the overall market. The rep…
December 21, 2017
Optogenetic Market Demonstrate Immense Growth Potential at ~176% of CAGR By 2023
This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the global Optogenetic Market over the forecast period. Posted via Industry Today. Follow us on Twitter @IndustryToday
Regenxbio Blogs
April 17, 2019
REGENXBIO Appoints Dr. Steve Pakola as Chief Medical Officer
REGENXBIO Appoints Dr. Steve Pakola as Chief Medical Officer
Content Import
Wed, 04/17/2019 - 07:04
REGENXBIO Appoints Dr. Steve Pakola as Chief Medical Officer
April 17, 2019 at 7:00 AM EDT
This release is a backfill from a News Wire
General
…
April 15, 2019
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2019 Annual Meeting
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2019 Annual Meeting
Content Import
Mon, 04/15/2019 - 16:08
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2019 Annual Meeting
April 15, 2019 at 4:05 PM …
February 27, 2019
REGENXBIO Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights
ROCKVILLE, Md. , Feb. 27, 2019 /PRNewswire/ -- Announces updates from recently expanded RGX-314 Phase I/IIa trial for wet AMD Completed dosing of six additional subjects in the fourth cohort for a total of 12 subjects; 30 subjects dosed across four cohorts in the trial On-track to initiate Phase
February 20, 2019
REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights
REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights
Content Import
Wed, 02/20/2019 - 07:06
REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full-Year 2018 Financial R…
January 31, 2019
REGENXBIO Receives Rare Pediatric Disease Designation for RGX-181 Gene Therapy for the Treatment of CLN2 Form of Batten Disease
REGENXBIO Receives Rare Pediatric Disease Designation for RGX-181 Gene Therapy for the Treatment of CLN2 Form of Batten Disease
Content Import
Thu, 01/31/2019 - 07:04
REGENXBIO Receives Rare Pediatric Disease Designation for RGX-181 Gene Therapy for the Treatment of CLN2 Form of Batten Dis…
January 04, 2019
REGENXBIO to Present at the 37th Annual J.P. Morgan Healthcare Conference
ROCKVILLE, Md. , Jan. 4, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology Platform, today announced that it will present at the 37 th
Regenxbio Frequently Asked Questions
When was Regenxbio founded?
Regenxbio was founded in 2009.
Who are Regenxbio key executives?
Regenxbio's key executives are Ken Mills, Vit Vasista and Stephen Yoo.
How many employees does Regenxbio have?
Regenxbio has 192 employees.
What is Regenxbio revenue?
Latest Regenxbio annual revenue is $218.5 m.
What is Regenxbio revenue per employee?
Latest Regenxbio revenue per employee is $1.1 m.
Who are Regenxbio competitors?
Competitors of Regenxbio include Syros Pharmaceuticals, ZIOPHARM Oncology and Oxford Genetics.
Where is Regenxbio headquarters?
Regenxbio headquarters is located at 9712 Medical Center Dr #100, Rockville.
Where are Regenxbio offices?
Regenxbio has an office in Rockville.
How many offices does Regenxbio have?
Regenxbio has 1 office.